Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399201 | 0.86 | MGLL (0.76) | MGLLFFAR4 | |
| SCHEMBL2429904 | 0.85 | MGLL (0.75) | MGLLFFAR4 | |
| SCHEMBL20397181 | 0.84 | MGLL (1.00) | MGLLFFAR4 | |
| SCHEMBL18421730 | 0.81 | MGLL (0.81) | MGLLFFAR4 | |
| SCHEMBL18418350 | 0.81 | MGLL (0.81) | MGLLFFAR4 | |
| SCHEMBL2427078 | 0.81 | MGLL (0.69) | MGLLFFAR4 | |
| SCHEMBL2428670 | 0.76 | MGLL (0.62) | MGLLFFAR4 | |
| SCHEMBL13363103 | 0.76 | MGLL (0.62) | MGLLFFAR4 | |
| SCHEMBL2426895 | 0.76 | MGLL (0.62) | MGLLFFAR4 | |
| SCHEMBL2422288 | 0.75 | MGLL (0.61) | MGLLFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571202-B1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3571202-B1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2018134698-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885FFAR4 3900/4885 |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885FFAR4 3900/4885 |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | MAG, MAGI3, APC | MGLL 16/4885FFAR4 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.